This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reis, F. M. Articles by Petraglia, F. Search for Related Content PubMed PubMed Citation Articles by Reis, F. M. Articles by Petraglia, F.

Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy

Chair of Obstetrics and Gynecology (F.P.), University of Siena, 53100 Siena, Italy; Department of Obstetrics and Gynecology (D.D.), University of Padua, 35128 Padua, Italy; and Department of Obstetrics and Gynecology (F.M.R.), University of Minas Gerais, Belo Horizonte 30130-100, Brazil

Correspondence: Address all correspondence and requests for reprints to: Felice Petraglia, M.D., Chair of Obstetrics and Gynecology, University of Siena Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy. E-mail: petraglia{at}unisi.it

Intrauterine tissues (placenta, amnion, chorion, decidua) express hormones and cytokines that play a decisive role in maternal-fetal physiological interactions. The excessive or deficient release of some placental hormones in association with gestational diseases may reflect an abnormal differentiation of the placenta, an impaired fetal metabolism, or an adaptive response of the feto-placental unit to adverse conditions. This review is focused on the applicability of hormone measurements in the risk assessment, early diagnosis, and management of pregnancies complicated by Down’s syndrome, fetal growth restriction, preeclampsia, preterm delivery, and diabetes mellitus. Combined hormonal tests or the combination of hormones and ultrasound may achieve reasonable sensitivity, but research continues to simplify the screening programs without sacrificing their accuracy. Only in a few instances is there sufficient evidence to firmly recommend the routine use of hormone tests to predict maternal and fetal complications, but the judicious use of selected tests may enhance the sensitivity of the risk assessment based solely on clinical and ultrasound examination.

This article has been cited by other articles:

				P Florio, P J Lowry, C Benedetto, L Galleri, M Torricelli, A Giovannelli, R Battista, F M Reis, and F Petraglia Maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) levels in post-term pregnancy: effect of prostaglandin administration Eur. J. Endocrinol., September 1, 2007; 157(3): 279 - 284. [Abstract] [Full Text] [PDF]

				A. Yin, E.H.Y. Ng, X. Zhang, Y. He, J. Wu, and K.Y. Leung Correlation of maternal plasma total cell-free DNA and fetal DNA levels with short term outcome of first-trimester vaginal bleeding Hum. Reprod., June 1, 2007; 22(6): 1736 - 1743. [Abstract] [Full Text] [PDF]

				P. Florio, F. M. Severi, C. Bocchi, S. Luisi, M. Mazzini, S. Danero, M. Torricelli, and F. Petraglia Single Serum Activin A Testing to Predict Ectopic Pregnancy J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1748 - 1753. [Abstract] [Full Text] [PDF]

				P. Florio, A. Imperatore, F. Sanseverino, M. Torricelli, F. M. Reis, P. J. Lowry, and F. Petraglia The Measurement of Maternal Plasma Corticotropin-Releasing Factor (CRF) and CRF-Binding Protein Improves the Early Prediction of Preeclampsia J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4673 - 4677. [Abstract] [Full Text] [PDF]

				P. Florio, F. M. Severi, G. Fiore, L. Micheli, C. Bocchi, C. Nencini, I. Pezzani, G. Giorgi, and F. Petraglia Impaired Uterine Artery Blood Flow at Mid Gestation and Low Levels of Maternal Plasma Corticotropin-Releasing Factor Reproductive Sciences, July 1, 2003; 10(5): 294 - 297. [Abstract] [PDF]